Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo
about
Antibodies inside of a cell can change its outside: Can intrabodies provide a new therapeutic paradigm?Specific in vivo knockdown of protein function by intrabodiesModern Technologies for Creating Synthetic Antibodies for Clinical application.Characterization of a novel angiogenic model based on stable, fluorescently labelled endothelial cell lines amenable to scale-up for high content screening.Generation of functional scFv intrabody to abate the expression of CD147 surface molecule of 293A cellsAntisense angiopoietin-1 inhibits tumorigenesis and angiogenesis of gastric cancer.An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer.Specific targeting of hepatitis C virus core protein by an intracellular single-chain antibody of human origin.A novel angiopoietin-derived peptide displays anti-angiogenic activity and inhibits tumour-induced and retinal neovascularization.VEGF silencing inhibits human osteosarcoma angiogenesis and promotes cell apoptosis via PI3K/AKT signaling pathway.Antibody-based antiangiogenic cancer therapy.Blocking translocation of cell surface molecules from the ER to the cell surface by intracellular antibodies targeted to the ER.Environmental risk factors for relapse of melanomaFrom rabbit antibody repertoires to rabbit monoclonal antibodiesResearch and development of next generation of antibody-based therapeuticsTargeting angiopoietin-2 signaling in cancer therapy.Gene-based antibody strategies for prion diseases.An active murine-human chimeric Fab antibody derived from Escherichia coli, potential therapy against over-expressing VEGFR2 solid tumors.Mining Naïve Rabbit Antibody Repertoires by Phage Display for Monoclonal Antibodies of Therapeutic Utility.Classical VEGF, Notch and Ang signalling in cancer angiogenesis, alternative approaches and future directions (Review).Recent Advances with ER Targeted Intrabodies.Cotargeting of VEGFR-1 and -3 and angiopoietin receptor Tie2 reduces the growth of solid human ovarian cancer in mice.Therapeutic Antibodies against Intracellular Tumor AntigensDifferential regulation of blood flow-induced neovascularization and mural cell recruitment by vascular endothelial growth factor and angiopoietin signalling.The use of phage display to generate conformation-sensor recombinant antibodies.Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release.Antisense Oligonucleotides Targeting Y-Box Binding Protein-1 Inhibit Tumor Angiogenesis by Downregulating Bcl-xL-VEGFR2/-Tie Axes.The potential for cancer combination therapy with multi-targeted, single-protein pharmaceuticals.VEGF Silencing Inhibits Human Osteosarcoma Angiogenesis and Promotes Cell Apoptosis via PI3K/AKT Signaling Pathway.
P2860
Q26738467-1279D587-7214-4A21-87EA-EA71FBE0173BQ26801077-76A74334-A708-464C-BD55-3D00DAD0BDA6Q30467308-2A7C8EA8-D29C-4968-A13B-91894F70DB4BQ30531493-652FBB70-4BCD-46D4-B7EF-B6DB037DC24FQ33316880-C1D0B49E-9EDA-4FA7-B3E4-0CC90DBF6C71Q33868913-63688FF6-216B-4BBB-8C32-82310C67E920Q34484368-B9C051EE-6C33-4A44-B2E4-804C7421AE4AQ34823264-26D09434-CADC-4227-B253-3F292F912319Q36025388-58B5824A-CE27-480C-B809-671CDFAD1F59Q36182716-B7EAC9AF-21AA-4E18-9F97-FB89ACCB7AA4Q36318555-9757AE59-19B3-4810-9083-F71DE0B6565DQ36762625-355DFECE-9AF5-4F35-972D-828F06D02372Q36973557-3B2C3A93-23BF-4841-8E20-932AB54E1B86Q37739483-BE0CEA1D-33E3-44EB-A3AF-276A77633F85Q37778732-57E4E985-DB2E-46C4-A3ED-BA6F05F0DF64Q38101997-3D11DAE7-6C71-43A1-9CB7-D371CAF24E92Q38136658-C883CFB9-BA61-41AA-82C3-C801330FD3C6Q38410220-5A4FCDB1-26B2-465B-BBCC-39E1B7F61E99Q38429183-38047A2F-8859-404D-BF0F-B73AA149790FQ38645097-1E31A8D5-5014-47A4-9595-4D800E7EF7F3Q38861174-2BC45D98-693D-4AD1-A452-DEF533D81F35Q39652101-4E34DCD6-5651-486A-8E25-414A3C794CD9Q41462883-2D43902F-D16E-451D-9B4D-0EC1BEBC7EFDQ42319216-CE62BDD7-F892-446A-948F-24349207B6C8Q43090031-92E77DF3-3A13-4D02-81A5-846AEF397828Q43202086-B201E595-0C61-4A54-8282-6527F6CA232DQ47156365-C9307BDF-5299-4E9A-9760-537EFF3AD9E8Q47952691-1D1CA5C7-861C-40DC-9BB8-A073C95E8136Q51676545-53278177-4799-4957-93E4-46EC35C7C4EA
P2860
Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Phenotypic knockout of VEGF-R2 ...... rowth and angiogenesis in vivo
@ast
Phenotypic knockout of VEGF-R2 ...... rowth and angiogenesis in vivo
@en
type
label
Phenotypic knockout of VEGF-R2 ...... rowth and angiogenesis in vivo
@ast
Phenotypic knockout of VEGF-R2 ...... rowth and angiogenesis in vivo
@en
prefLabel
Phenotypic knockout of VEGF-R2 ...... rowth and angiogenesis in vivo
@ast
Phenotypic knockout of VEGF-R2 ...... rowth and angiogenesis in vivo
@en
P2093
P2860
P356
P1476
Phenotypic knockout of VEGF-R2 ...... rowth and angiogenesis in vivo
@en
P2093
Carlos F Barbas
Mikhail Popkov
Nina Jendreyko
P2860
P304
P356
10.1073/PNAS.0503168102
P407
P577
2005-05-31T00:00:00Z